Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine hydrochloride is an alpha‑1 adrenergic receptor agonist. By stimulating these receptors on the radial iris dilator muscle, it causes the muscle to contract, pulling the iris outward and contributing to pupil enlargement when combined with tropicamide.

The appropriate dose of Mydriasert is determined by the prescribing eye care professional based on the specific examination needs and patient characteristics. The prescriber will select the number of drops and timing required for adequate mydriasis.

Safety data for Mydriasert in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician after evaluating the individual situation.

To order Mydriasert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mydriasert combines an alpha‑1 agonist (phenylephrine) with a muscarinic antagonist (tropicamide), offering rapid and sustained dilation. Compared with single‑agent drops such as tropicamide alone, the combination often achieves quicker onset and greater pupil size, which can be advantageous for time‑sensitive examinations.

Mydriasert should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Keep the container tightly closed when not in use and discard any solution that appears discolored or contaminated.

Mydriasert is applied topically to the eye as an ophthalmic solution. The prescriber will instruct the patient on the number of drops per eye and the interval between applications, typically instilling the drops directly onto the conjunctival sac.

The most serious risks include acute angle‑closure glaucoma, severe allergic reactions such as anaphylaxis, and systemic hypertension. Patients should be monitored for signs of these conditions, and the medication should be discontinued immediately if they occur.

Mydriasert should not be used in patients with known hypersensitivity to phenylephrine, tropicamide, or any excipients, nor in individuals with narrow‑angle or uncontrolled glaucoma, severe cardiovascular disease, or those taking monoamine oxidase inhibitors without medical supervision.